EMEA-002573-PIP01-19

Key facts

Active substance
EGFR-cMET bispecific antibody
Therapeutic area
Oncology
Decision number
P/0289/2019
PIP number
EMEA-002573-PIP01-19
Pharmaceutical form(s)
  • Concentrate for solution for infusion
  • Solution for injection
Condition(s) / indication(s)
Treatment of lung carcinoma
Route(s) of administration
Intravenous use
Contact for public enquiries
Janssen-Cilag International NV
Ireland
Tel. +353 857446696
E-mail: nbuhl@its.jnj.com

 
Decision type
W: decision granting a waiver in all age groups for all conditions/indications

Decision

How useful was this page?

Add your rating